Objective:

To summarize recent developments in the pharmaceutical industry, including regulatory changes, corporate restructuring, and financial transactions.

Approach:

• Regulation: FDA Commissioner Scott Gottlieb announced plans to close a loophole allowing companies to avoid pediatric study requirements under the Pediatric Research Equity Act (PREA) and the Orphan Drug Act (ODA).
• UK Life Sciences: The UK Life Sciences Industrial Strategy Board published a report advocating for close ties with the EMA post-Brexit, citing the small size of the UK market.
• Manufacturing: Eli Lilly plans to cut 3,500 jobs and close several facilities to save $500 million, with total costs expected to reach $1.2 billion pre-tax.
• Controversies: Allergan transferred patents for its dry eye drug Restasis to the Saint Regis Mohawk Tribe to avoid patent challenges due to the tribe's sovereign immunity.
• Pharmaceutical Payments in Australia: A report revealed that Australian pharmaceutical companies paid AU$12 million to healthcare professionals between November 2016 and April 2017.

Key Findings:

• FDA aims to close a loophole in pediatric drug study requirements.
• UK life sciences industry seeks collaboration with EMA post-Brexit.
• Eli Lilly to reduce workforce and close facilities to cut costs.
• Allergan's patent transfer strategy to avoid legal challenges.
• Pharmaceutical companies in Australia made significant payments to healthcare professionals.

Interpretation:

Limitations:

• The article does not provide detailed outcomes or implications of the FDA's regulatory changes.
• No specific data on the impact of Eli Lilly's job cuts on its operations or market position.

Conclusion:

Recent actions by pharmaceutical companies reflect a complex landscape of regulatory compliance, corporate restructuring, and financial strategies.

Sources:

• FDA Announcement
• UK Life Sciences Report
• Eli Lilly Job Cuts
• Allergan Patent Transfer
• Pharmaceutical Payments in Australia